Cosentyx® is the first new biologic treatment for hidradenitis suppurativa in nearly a decade, offering clinically meaningful results across the most debilitating. | June 1, 2023
Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa • Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly a decade • Committee for Medicinal Products for Human Use (CHMP) opinion based.
Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly a decade Committee for Medicinal Products for Human Use (CHMP) opinion based on robust Phase
Positive opinion paves way for first new treatment option in hidradenitis suppurativa in nearly a decade Committee for Medicinal Products for Human Use opinion based on robust Phase III data. | April 26, 2023